These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31540142)

  • 21. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stroke in the patient with diabetes (Part 2) - Prevention and the effects of glucose lowering therapies.
    Bell DSH; Goncalves E
    Diabetes Res Clin Pract; 2020 Jun; 164():108199. PubMed ID: 32413380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihyperglycemic drugs use and new-onset atrial fibrillation in elderly patients.
    Chen HY; Yang FY; Jong GP; Liou YS
    Eur J Clin Invest; 2017 May; 47(5):388-393. PubMed ID: 28369870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left atrial appendage occlusion for stroke prevention in diabetes mellitus patients with atrial fibrillation: Long-term results.
    Litwinowicz R; Bartus M; Ceranowicz P; Brzezinski M; Kapelak B; Lakkireddy D; Bartus K
    J Diabetes; 2019 Jan; 11(1):75-82. PubMed ID: 29999242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between glycemic control assessed by continuous glucose monitoring and stroke in patients with atrial fibrillation and diabetes mellitus.
    Guo J; Wang J; Zhao Z; Yu L
    Ann Palliat Med; 2021 Aug; 10(8):9157-9164. PubMed ID: 34488401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Yao X; Gersh BJ; Sangaralingham LR; Shah ND; Noseworthy PA
    Am Heart J; 2018 May; 199():137-143. PubMed ID: 29754652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
    Du X; Ninomiya T; de Galan B; Abadir E; Chalmers J; Pillai A; Woodward M; Cooper M; Harrap S; Hamet P; Poulter N; Lip GY; Patel A;
    Eur Heart J; 2009 May; 30(9):1128-35. PubMed ID: 19282274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF).
    Silberberg A; Tan MK; Yan AT; Angaran P; Dorian P; Bucci C; Gregoire JC; Bell AD; Gladstone DJ; Green MS; Gross PL; Skanes A; Demchuk AM; Kerr CR; Mitchell LB; Cox JL; Talajic M; Essebag V; Heilbron B; Ramanathan K; Fournier C; Wheeler BH; Lin PJ; Berall M; Langer A; Goldin L; Goodman SG;
    Am J Cardiol; 2017 Aug; 120(4):582-587. PubMed ID: 28666577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation.
    Patti G; Sticchi A; Pasceri V; Ricci F; Renda G; Hamrefors V; Melander O; Sutton R; Engström G; De Caterina R; Fedorowski A
    Diabetes Metab Res Rev; 2019 Jul; 35(5):e3145. PubMed ID: 30790434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review.
    Käräjämäki AJ; Hukkanen J; Ukkola O
    Ann Med; 2018 Aug; 50(5):371-380. PubMed ID: 29929399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
    Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidiabetic drugs and stroke risk. Current evidence.
    Castilla-Guerra L; Fernandez-Moreno MDC; Leon-Jimenez D; Carmona-Nimo E
    Eur J Intern Med; 2018 Feb; 48():1-5. PubMed ID: 28939005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dronedarone for the treatment of atrial fibrillation and atrial flutter.
    Maund E; McKenna C; Sarowar M; Fox D; Stevenson M; Pepper C; Palmer S; Woolacott N
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):55-62. PubMed ID: 21047492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.